Overview Request Sample Pages Request Customization Download PDF
You are viewing: South Korea Bioinformatics Market analysis
Part of: Bioinformatics Market (Global)

The South Korea Bioinformatics Market was valued at $277.9 Million in 2026 and projected to reach to $518.3 Million by 2031, representing a compound annual growth rate of 13.3%. South Korea's bioinformatics market is poised for substantial growth, expanding from USD 277.9 million in 2026 to USD 518.3 million by 2031.

South Korea Bioinformatics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Bioinformatics Market Trends and Insights

  • This growth trajectory reflects South Korea's strategic investments in genomic research, personalized medicine, and healthcare digitalization.
  • South Korea's advanced IT infrastructure and strong pharmaceutical sector position the nation as a key bioinformatics hub in Asia Pacific. The bioinformatics sector in South Korea is driven by increasing adoption of next-generation sequencing (NGS) technologies, rising prevalence of chronic diseases, and government support for precision medicine initiatives.
  • South Korea's research institutions and biotech companies are leveraging bioinformatics tools to accelerate drug discovery and development.
  • Between 2026 and 2031, South Korea is expected to see heightened demand for data analytics platforms, clinical decision support systems, and genomic databases. South Korea's competitive advantage stems from its skilled workforce, robust venture capital ecosystem, and collaborative partnerships between academia and industry.
  • South Korea continues to attract international bioinformatics vendors and foster domestic innovation, solidifying its position as a regional leader in healthcare technology and life sciences..

Key Market Statistics

  • CAGR (2026-2031) 13.3% CAGR
  • Market Size, 2026 ~USD 277.9 Million
  • Forecast, 2031 ~USD 518.3 Million
  • Country South Korea

South Korea Bioinformatics Market Overview

Strong Market Valuation :

South Korea's bioinformatics market is valued at USD 277.9 million in 2026, demonstrating significant market maturity and investment in genomic technologies within the region.

Robust Growth Trajectory :

With a CAGR of 13.3% from 2026 to 2031, South Korea's bioinformatics market is expanding faster than the global average of 13.1%, reflecting accelerated adoption of advanced healthcare solutions.

Advanced IT Infrastructure :

South Korea's world-class digital infrastructure and high-speed connectivity enable seamless implementation of bioinformatics platforms, supporting personalized medicine and genomic research initiatives.

Pharmaceutical Sector Leadership :

The nation's robust pharmaceutical industry drives demand for bioinformatics solutions in drug discovery, clinical trials, and precision medicine applications, positioning South Korea as a regional innovation hub.

South Korea Bioinformatics Market Dynamics

  • This expansion is driven by government initiatives supporting genomic research, increasing healthcare digitalization, and growing adoption of personalized medicine approaches across hospitals and research institutions. The market benefits from South Korea's technological prowess, skilled workforce, and strategic investments in life sciences infrastructure.
  • Key growth drivers include rising demand for precision diagnostics, integration of AI in genomic analysis, and collaborations between biotech companies and healthcare providers.
  • The nation's commitment to becoming a global bioinformatics leader ensures sustained market momentum through 2031..

Market Ecosystem

logo-mobile

BIOINFORMATICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides bioinformatics solutions for genomic data analysis, next-generation sequencing (NGS) workflows, molecular diagnostics, and life science research. Its platforms support sequencing data interpretation, variant analysis, and clinical research applications. Faster genomic data analysis, improved accuracy in variant interpretation, streamlined NGS workflows, enhanced research productivity, and support for precision medicine development.
Offers integrated sequencing and bioinformatics platforms for analyzing large-scale genomic data. Its solutions support applications in oncology, inherited disease research, population genomics, and clinical diagnostics through advanced sequencing data analysis. Efficient management of complex genomic datasets, improved disease identification, faster biomarker discovery, enhanced clinical decision-making, and acceleration of personalized medicine.
Provides bioinformatics software and genomic analysis platforms for sample-to-insight workflows, molecular diagnostics, clinical research, and next-generation sequencing data interpretation. Simplified data analysis, improved workflow automation, reliable genomic insights, reduced analysis time, and enhanced support for molecular testing and precision healthcare.
Develops bioinformatics tools for genomics, transcriptomics, and molecular analysis, supporting applications such as microarray analysis, NGS data interpretation, and biomarker discovery in research and clinical settings. Improved data visualization and interpretation, increased research efficiency, accurate molecular profiling, faster discovery of biological insights, and optimized laboratory workflows.
Provides integrated bioinformatics solutions supporting clinical genomics, companion diagnostics, oncology research, and precision medicine. Its platforms enable genomic data analysis for targeted therapies and biomarker identification. Enhanced biomarker assessment, faster treatment decisions, improved diagnostic accuracy, optimized clinical workflows, and support for personalized medicine approaches.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • Merck KGaA
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • South Korea's bioinformatics market will nearly double from USD 277.9M (2026) to USD 518.3M (2031), representing a 13.3% CAGR.
      • South Korea's advanced IT infrastructure and genomic research capabilities position it as a leading bioinformatics market in Asia Pacific.
      • South Korea's government-backed precision medicine initiatives and NGS adoption are primary growth catalysts through 2031.
      • South Korea's skilled biotech workforce and strong academia-industry partnerships drive innovation and attract global bioinformatics vendors.

      Bioinformatics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment PRECISION MEDICINE (Use Case)
      Forecast Period 2026-2031
      Growth Rate CAGR of 13.1% from 2026 to 2031
      Largest Segment SOFTWARE (Offering)
      Market Size Base Year (Billions) ~USD 18.59 (2026)
      Revenue Forecast (Billions) ~USD 34.41 (2031)
      Segments Covered Offering, Type, Function, Use Case, Sector, End User

      South Korea Bioinformatics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Offering

      • Services
      • Software

      By Type

      • Chemoinformatics Solutions
      • Cloud & Managed Bioinformatics
      • Cloud & Managed Services
      • Consulting & Custom Bioinformatics Development
      • Data Analysis & Interpretation
      • Database & Data Management
      • Drug Discovery & Target Identification
      • End-To-End Solutions
      • Gene Expression Analysis
      • Generalized Knowledge Management Tools
      • Genomics Solutions
      • Knowledge Management Tool
      • Metabolomics Solutions
      • Multi-Omics Solutions
      • Multiomics Solutions
      • Niche Point Solutions
      • Other Bioinformatics Services
      • Other Data Analysis Functions
      • Other End-To-End Solutions
      • Other Services
      • Proteomics Solutions
      • Sequence Analysis
      • Sequencing & Data Generation
      • Specialized Knowledge Management Tools
      • Transcriptomics Solutions
      • Variant Analysis

      By Function

      • Clinical Interpretation
      • Data Analysis
      • Data Visualization & Reporting
      • Multiomics Integration
      • Other Functions
      • Structural & Functional Analysis

      By Use Case

      • Biomarker Discovery
      • Clinical Diagnostics
      • Drug Discovery & Development
      • Other Use Cases
      • Precision Medicine
      • Research & Academic Applications

      By Sector

      • Animal Biotechnology
      • Environmental Biotechnology
      • Forensic Biotechnology
      • Medical Biotechnology
      • Other Sectors
      • Plant Biotechnology

      By End User

      • Academic & Research Institutes
      • Contract Research Organizations And Contract Development & Manufacturing Organizations
      • Government & Public Health Organizations
      • Hospitals & Clinical Diagnostic Laboratories
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      Target Audience

      • Bioinformatics Software Vendors : Evaluate South Korea's market potential for genomic analysis platforms, clinical decision support systems, and data management solutions targeting hospitals and research centers.
      • Pharmaceutical & Biotech Companies : Assess opportunities for drug discovery acceleration, clinical trial optimization, and precision medicine development leveraging South Korea's advanced bioinformatics infrastructure.
      • Healthcare Providers & Hospitals : Understand bioinformatics implementation strategies for personalized diagnostics, genomic testing services, and precision treatment planning to enhance patient outcomes in South Korea.
      • Investment & Private Equity Firms : Identify high-growth investment opportunities in South Korean bioinformatics startups, healthcare IT companies, and genomic research initiatives with strong market fundamentals.
      • Government & Research Institutions : Leverage market data to inform policy decisions, research funding allocation, and strategic initiatives supporting South Korea's position as a global bioinformatics innovation leader.

      Key Companies in the South Korea Bioinformatics Market

      CompanyHQOwnershipStrongest segments
      BECKMAN COULTERUnited StatesPrivate CompanyBioinformatics Software (Genomics, Multiomics, Proteomics),Bioinformatics Services (Analysis, Sequencing, Genomic Services),
      WUXI APPTECChinaPublic CompanyChemical Business,Testing Services,Biological Services,
      DANAHER CORPORATIONUnited StatesPublic CompanyDiagnostics,Life Sciences (Excl. Biotechnology),Biotechnology,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing and array-based instruments,Consumables (reagents, flow cells, library preparation, WGS and targeted kits),Services (whole-genome sequencing, genotyping, NIPT, product support, informatics services),
      QIAGEN N.V.NetherlandsPublic CompanyBioinformatics software (genomics, multiomics, proteomics),Bioinformatics-linked services (analysis, sequencing, interpretation),Non-bioinformatics consumables and instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyAgilent CrossLab,Life Sciences and Diagnostics Markets,Applied Markets,
      REVVITY, INC.United StatesPublic CompanyLife Sciences,Diagnostics,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyBioinformatics-linked genomics and multiomics services,Non-informatics analytical testing (food, environment, consumer, other),
      BGI GENOMICSChinaPublic CompanySequencing and Bioinformatics Services,Clinical Testing and Precision Medicine Solutions,Mass Spectrometry and Multi-omics (Proteomics, Metabolomics, Multi-omics Integration),
      WATERS CORPORATIONUnited StatesPublic CompanyWaters Segment (LC-MS systems, consumables, and software),Materials Sciences Division (thermal analysis, rheometry, calorimetry),
      OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanySequencing instruments (MinION, GridION, PromethION),Consumables and flow cells,Software and bioinformatics services,
      10X GENOMICSUnited StatesPublic CompanySingle-cell and spatial instruments (Chromium, Chromium X Series, Visium, Xenium Analyzer, CytAssist),Consumables and reagents (microfluidic chips, slides, kits including QuantumScale),Bioinformatics software and analysis services (Cell Ranger, Loupe Browser, Xenium Explorer, associated analysis support),
      PACBIOUnited StatesPublic CompanySequencing instruments (Revio, Vega, Sequel, Onso),Consumables (SMRT cells, SMRTbell prep kits, binding and sequencing kits),Software and services (bioinformatics analysis, sequencing services, collaborations),
      SIEMENS AGGermanyPublic CompanyIndustrial Businesses (IB) - Siemens Healthineers,Industrial Businesses (IB) - Smart Infrastructure,Industrial Businesses (IB) - Digital Industries,
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM Software Platform (Genomics, Multiomics, Proteomics),Services (Analysis Support, Sequencing-Linked Informatics, Implementation),

      BECKMAN COULTER

      Beckman Coulter is a private American company founded in 1935 that employs 11,900 people. The company operates in the life sciences and diagnostics sector.

      WUXI APPTEC

      WuXi AppTec is a public Chinese company founded in 2000 with 35,584 employees. The company provides pharmaceutical and biotechnology research and development services.

      DANAHER CORPORATION

      Danaher Corporation is a public American company founded in 1969 with 59,000 employees. The company operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public American company founded in 1956 with 125,000 employees. The company is a leading provider of laboratory equipment, reagents, and services for life sciences research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is a public American company founded in 1998 with 8,625 employees. The company specializes in DNA sequencing and genetic analysis technologies.

      QIAGEN N.V.

      QIAGEN N.V. is a public Dutch company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences products.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public American company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      REVVITY, INC.

      Revvity, Inc. is a public American company founded in 1937 with 11,000 employees. The company provides analytical instruments and life sciences solutions.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public Luxembourg-based company founded in 1987 with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.

      BGI GENOMICS

      BGI Genomics is a public Chinese company founded in 1999 with 3,580 employees. The company specializes in genomic sequencing and genetic analysis services.

      WATERS CORPORATION

      Waters Corporation is a public American company founded in 1958 with 7,900 employees. The company manufactures analytical instruments and software for laboratory testing and research.

      OXFORD NANOPORE TECHNOLOGIES PLC

      Oxford Nanopore Technologies PLC is a public British company founded in 2005 with 1,316 employees. The company develops nanopore-based DNA and RNA sequencing technologies.

      10X GENOMICS

      10X Genomics is a public American company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions for research and diagnostics.

      PACBIO

      PacBio is a public American company founded in 2000 with 485 employees. The company develops long-read DNA sequencing technologies and systems.

      SIEMENS AG

      Siemens AG is a public German company founded in 1847 with 317,000 employees. The company operates across multiple sectors including industrial automation, energy, healthcare, and infrastructure.

      SOPHIA GENETICS

      Sophia Genetics is a public Swiss company founded in 2011 with 415 employees. The company provides AI-powered genomic analysis and interpretation software for clinical diagnostics.

      Reasons to Buy this Report

      • Market-Specific Growth Insights : Gain detailed understanding of South Korea's 13.3% CAGR trajectory and USD 240.4 million market expansion opportunity between 2026-2031, enabling precise investment and expansion strategies.
      • Competitive Landscape Analysis : Identify key players, market consolidation trends, and competitive positioning specific to South Korea's bioinformatics ecosystem, including local and international competitors.
      • Regulatory & Policy Framework : Understand South Korea's unique regulatory environment, government incentives for genomic research, and healthcare policies shaping bioinformatics adoption and market dynamics.
      • Technology & Application Trends : Discover emerging bioinformatics applications in South Korean healthcare, including AI integration, precision diagnostics, and personalized medicine adoption rates specific to the region.
      • Strategic Partnership Opportunities : Identify collaboration potential with South Korean pharmaceutical companies, research institutions, and healthcare providers to accelerate market entry and establish regional presence.

      Frequently asked questions

      What is the projected size of South Korea's bioinformatics market by 2031?

      South Korea's bioinformatics market is projected to reach USD 518.3 million by 2031, up from USD 277.9 million in 2026.

      What is the CAGR for South Korea's bioinformatics market?

      South Korea's bioinformatics market is expected to grow at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2031.

      What are the main drivers of growth in South Korea's bioinformatics market?

      Key growth drivers in South Korea include increased NGS adoption, government precision medicine initiatives, rising chronic disease prevalence, and strong investments in genomic research infrastructure.

      Why is South Korea a significant bioinformatics market?

      South Korea's advanced IT infrastructure, skilled workforce, robust pharmaceutical sector, and government support for healthcare innovation make it a leading bioinformatics hub in Asia Pacific.

      What bioinformatics solutions are in high demand in South Korea?

      South Korea shows strong demand for NGS data analysis platforms, clinical decision support systems, genomic databases, and personalized medicine analytics tools.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of both primary and secondary sources. It analyzed various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

      Secondary Research

      This research study extensively used secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive, commercially focused study of the bioinformatics market, covering technical aspects and market dynamics. It also helped identify key players, market classifications, industry trends, geographic markets, and significant market developments. Additionally, a database of prominent industry leaders was compiled through secondary research.

      Primary Research

      In the primary research process, various supply-side and demand-side sources were interviewed to gather qualitative and quantitative information for this report. Primary supply-side sources included industry experts such as CEOs, VPs, managing directors, marketing and sales heads/directors, marketing managers, regional/area sales managers, and bioinformatics scientists. Primary demand-side sources included personnel from pharmaceutical and biotechnology companies, hospitals, diagnostic laboratories, and academic and research institutes.

      A breakdown of the primary respondents is provided below:

      Bioinformatics Market Size, and Share

      *Others include sales managers, marketing managers, and product managers.
      Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the bioinformatics market was determined after data triangulation using the two approaches outlined below. After each approach was completed, the weighted average of the two approaches was calculated based on the level of assumptions used in each approach.

      Bioinformatics Market : Top-Down and Bottom-Up Approach

      Bioinformatics Market Top Down and Bottom Up Approach

      Data Triangulation

      The size of the bioinformatics market was estimated through segmental extrapolation using the bottom-up approach. The methodology is as follows:

      • Revenue information of individual companies was gathered from public sources and databases.
      • The share of leading players in the bioinformatics market was obtained from secondary sources to the extent available. In certain cases, shares of bioinformatics businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach and strength. 
      • Individual shares or revenue estimates were validated through interviews with experts.
      • The total revenue in the bioinformatics market was determined by extrapolating the market share data of major companies.

      Market Definition

      Bioinformatics is the application of computer technology to the management and analysis of biological data. It encompasses the storage, analysis, and dissemination of biological data. Bioinformatics uses computer programs for a variety of applications, including determining gene and protein functions, establishing evolutionary relationships, and predicting the three-dimensional shapes of proteins.

      Key Stakeholders

      • Bioinformatics software and service providers
      • Academic & research institutes
      • Clinical & diagnostic laboratories
      • Hospitals & healthcare providers
      • Contract research organizations (CROs)
      • Distributors and suppliers of bioinformatics software and services
      • Pharmaceutical & biotechnology companies
      • Market research and consulting firms
      • Venture capitalists

      Report Objectives

      • To define, describe, and forecast the bioinformatics market based on offering, function, use case, sector, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall bioinformatics market
      • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa.
      • To profile the key players and analyze their market share and core competencies2
      • To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall bioinformatics market
      • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

      • Company Information
      • Detailed analysis and profiling of additional market players (up to 5)

      Product Analysis

      • Further breakdown of the Rest of Asia Pacific market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
      • Further breakdown of the Rest of Europe bioinformatics market into Russia, Austria, Finland, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries

      Get the Full Bioinformatics Market Report

      Full forecast, segment splits, and company analysis for all Bioinformatics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status